Streetbeat News

Stock Prices

NVO

Novo Nordisk shares are trading lower following worse-than-expected Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:39 am

PAYO

Payoneer Global shares are trading higher after the company reported strong Q2 financial results and raised its guidance.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:37 am

EHTH

eHealth shares are trading higher after the company reported better-than-expected Q2 sales results and issued FY24 revenue guidance above estimates.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:37 am

MMI

Marcus & Millichap (NYSE:MMI) reported Q2 GAAP EPS of $(0.14), beating the $(0.15) estimate, but missed sales estimates with $158.37M, a 2.76% decrease from last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:36 am

SGHC

Super Group (SGHC) reported Q2 2024 GAAP EPS of $(0.17), missing the $0.10 estimate by 270%. However, sales of $446.520M beat the $402.475M estimate by 10.94%, marking a 7.59% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:36 am

PAYO

Payoneer Global has updated its FY24 guidance, projecting revenue between $920M and $930M, up from the prior estimate of $895M-$905M. Transaction costs are expected to be around 16.5% of revenue, down from the previous 17.5%. Adjusted EBITDA is forecasted to be between $225M and $235M, an increase from the prior $200M-$210M.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:34 am

EYPT

EyePoint Pharmaceuticals has reported cash and investments totaling $280.2 million, which is expected to provide a cash runway into 2026.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:34 am

GFF

Griffon (NYSE:GFF) reported Q3 2024 adjusted EPS of $1.24, missing the analyst estimate of $1.31. Sales were $647.8 million, also below the $688.94 million estimate and down 5.21% from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:33 am

EHTH

eHealth has projected its FY24 revenue to be between $470 million and $495 million, surpassing the estimated $466.574 million.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:33 am

EYPT

EyePoint Pharmaceuticals reported Q2 2024 GAAP EPS of $(0.58), missing the $(0.53) estimate. Sales were $9.477M, also missing the $9.593M estimate.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:33 am